- A. Health Biotechnology
- Areas of activity
- Therapeutic areas
- Cardiovascular diseases and circulatory system
- Kidney and genitourinary system
Sanifit offers a new approach to calcification disorders. The Rx pipeline focus is on severe renal diseases and soft tissue calcification.
The experienced management team has proven track record and large pharma/biotech experience.
The business model is to develop the products up to clinical prove of concept and out-license/partner final development and commercialization.
SNF472 (lead product): Phase I clinical trials are scheduled 2013, PhII 2014-16. It targets renal disease, dialysis patients reducing calcification and cardiovascular events, indications with high medical need and blockbuster potential.
In addition an orphan drug development with SNF472 is in progress. Orphan drug designation was granted by EMA and FDA in August and December 2012 respectively.
The preclinical pipeline aims at major renal/CV areas, CKD and kidney stones.
The IP protected technology covers also the use in medical nutrition and medical devices, where Sanifit develops applications jointly with partners.
OTC dental care products with outstanding clinical efficacy were successfully developed and are in the commercial partnering phase.